Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration

Abstract Objectives The duration of administration (e.g., subchronic or chronic) haloperidol may influence its adverse effects. We studied the effects on body weight and fasting blood sugar (FBS). In addition, we examined whether orally administered cannabidiol (CBD) had any putative mitigating haloperidol-induced changes FBS elevation. Methods Haloperidol (5 mg/kg/day) was for 21 days (subchronic administration), via intraperitoneal (IP) route, monthly (50 mg/kg monthly) 3 months (chronic intramuscular (IM) either alone before CBD mg/kg/day). Oral distilled water were days. Weight measured pharmacological agents (distilled in control group) post-administration. Results Group differences average across time significant. Pairwise comparisons showed that mean group (Group A) chronic F) increased significantly over time. Post medications, there a significant increase compared to group. There also reduction from baseline only. Conclusion demonstrated influenced rats, suggesting metabolic side effects, be by administration. ameliorated observed groups.